VEGFA and colonic neoplasm: Bevacizumab, is an anti-vascular endothelial growth factor (VEGF) monoclonal antibody used to treat metastatic rectal, breast and colon cancer, stops angiogenesis by sequestering soluble VEGF and inhibiting antibodies targeting different epitopes of the same protein from binding to VEGFR-2 [138].